Sign In
Buy ERAS
$18.15
-0.530 (-2.84%)
At Close: Jul 31, 2026
ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
10:11am, Monday, 20'th Jul 2026
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Erasca, Inc. (NASDAQ: ERAS) of a pending securities class action. Class Period: January 14, 2025 through April 26,
SAN FRANCISCO, July 20, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 202
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired
New York, New York--(Newsfile Corp. - July 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 20
NEW YORK, July 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and Apri
New York, New York--(Newsfile Corp. - July 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 20
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
10:45pm, Friday, 17'th Jul 2026
NEW YORK, July 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26
/PRNewswire/ -- - Kahn Swick and Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point
05:14pm, Friday, 17'th Jul 2026
Erasca, Inc. offers exposure to the RAS/MAPK oncology space at a fraction of Revolution Medicines' valuation, with a $6.7bn market cap versus RVMD's $38.5bn. ERAS-0015's Phase 1 data show promising ef
Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of a Securities Class Action Deadline on August 10, 2026
04:30pm, Friday, 17'th Jul 2026
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS)
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies i
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired
SAN FRANCISCO, July 17, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc
ERAS DEADLINE: The Gross Law Firm Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
10:27am, Friday, 17'th Jul 2026
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS).
